Related Experiment Video
Updated: Sep 12, 2025
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Unlocking the potential: tissue mutation abundance as a predictor for third-generation EGFR-TKI efficacy in NSCLC
Ruiqi Wang1, Hongfei Wei2, Chunjing Qu3
1Department of Hematology and Oncology, China-Japan Union Hospital of Jilin University, Changchun 130033, China; Department of Hematology, the First Hospital of Jilin University, Changchun 130021, China.
Tissue mutation abundance is a key predictor of third-generation EGFR-TKI efficacy in non-small cell lung cancer (NSCLC). High abundance correlates with longer progression-free survival, while low abundance may indicate resistance, necessitating personalized treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Third-generation EGFR-TKIs are first-line treatments for unresectable NSCLC with EGFR mutations.
- The role of tissue mutation abundance in predicting TKI efficacy remains underexplored.
- Optimizing targeted therapies requires understanding factors influencing treatment response.
Purpose of the Study:
- To compare the efficacy of first-line third-generation EGFR-TKIs based on tissue mutation abundance in NSCLC patients.
- To identify predictors of treatment response and progression-free survival.
Main Methods:
- Retrospective analysis of 159 unresectable NSCLC patients with EGFR-sensitive mutations.
- Comparison of treatment response and median progression-free survival (mPFS) between high and low mutation abundance groups.
- Univariate and multivariate analyses to identify risk factors for mPFS.
Main Results:
- High mutation abundance group showed significantly higher objective response rates (88% vs. 66.7%) and disease control rates (97.2% vs. 80.4%).
- The high-abundance group had a longer mPFS (22 months vs. 17 months).
- Disease progression patterns were similar between groups, with no statistical significance.
Conclusions:
- Tissue mutation abundance is a significant predictor of third-generation TKI efficacy in EGFR-mutated NSCLC.
- High mutation abundance is associated with superior treatment outcomes and longer mPFS.
- Further research is needed for personalized treatment strategies based on mutation abundance and other factors.
